St Jude's bipolar lead for CRT (cardiac resynchronisation therapy) devices:
This article was originally published in Clinica
Executive Summary
The US FDA has given St Jude Medical the all-clear to sell its QuickSite 1056T bipolar lead, a product designed for use with the company's Epic and Atlas cardiac resynchronisation therapy (CRT) devices for treating heart failure. "The bipolar lead leverages the clinically proven design of the QuickSite unipolar lead, adding the flexibility of bipolar pacing to better manage patients with phrenic nerve stimulation," said Michael Coyle, president of the St Paul, Minnesota firm's cardiac rhythm management division. The product is scheduled for launch in May 2005.